 |
Products |  |
Diseases | | Products |
|
Trials |  |
News |  |
- MVX-ONCO-1 / Release Therap
Long term survival data from all Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) patients treated with MVX-ONCO-1 during open-labelled Phase I and Phase IIA clinical trials (Foyer mezzanine) - Oct 23, 2024 - Abstract #ESMOIO2024ESMO_IO_259;
- | MVX-ONCO-2 / MaxiVAX
Enrollment open, Trial completion date, Trial primary completion date: MVX-ONCO-2 in Advanced Solid Tumors (clinicaltrials.gov) - Oct 15, 2024
P1, N=6, Recruiting, Sponsor: Eugenio Fernandez
Withdrawn --> Recruiting | Trial completion date: Dec 2027 --> Oct 2029 | Trial primary completion date: Jul 2023 --> Oct 2025
- || MVX-ONCO-1 / Release Therap
P1 data, Journal, Metastases: A first-in-human phase I clinical study with MVX-ONCO-1, a personalized active immunotherapy, in patients with advanced solid tumors. (Pubmed Central) - Jul 23, 2024
Conclusion/Discussion MVX-ONCO-1 is safe, well-tolerated, and beneficial across several tumor types. Ongoing phase IIa trials target advanced R/M HNSCC patients post initial systemic therapy.
- || MVX-ONCO-1 / Release Therap
Trial completion, Trial completion date, Metastases: SAKK 11/16: Personalized and Cell-based Antitumor Immunization MVX-ONCO-1 in Advanced HNSCC (clinicaltrials.gov) - Sep 28, 2023
P2, N=16, Completed, Sponsor: Maxivax SA
Ongoing phase IIa trials target advanced R/M HNSCC patients post initial systemic therapy. Active, not recruiting --> Completed | Trial completion date: Dec 2027 --> Jun 2023
- MVX-ONCO-1 / MaxiVAX
SAKK 11/16, a phase IIa trial evaluating overall survival (OS) for recurrent/metastatic Head & neck squamous cell carcinoma (RMHNSCC) patients (pts) progressing after ? 1 line of systemic therapy, treated with MVX-ONCO-1, a novel, first in class cell encapsulation-based immunotherapy (M) - Jul 27, 2023 - Abstract #ESMO2023ESMO_472;
P2
Prolonged OS correlates strongly with immune education, DTH being a potential biomarker to be validated in future studies. MVX-ONCO-1 is the first cancer vaccine associated with prolonged survival in advanced chemo / IO refractory disease in monotherapy without maintenance.
- ||| MVX-ONCO-2 / MaxiVAX
Trial withdrawal: MVX-ONCO-2 in Advanced Solid Tumors (clinicaltrials.gov) - Jan 30, 2023
P1, N=0, Withdrawn, Sponsor: Maxivax SA
MVX-ONCO-1 is the first cancer vaccine associated with prolonged survival in advanced chemo / IO refractory disease in monotherapy without maintenance. Not yet recruiting --> Withdrawn
- | MVX-ONCO-1 / Release Therap
Enrollment closed, Trial primary completion date, Metastases: SAKK 11/16: Personalized and Cell-based Antitumor Immunization MVX-ONCO-1 in Advanced HNSCC (clinicaltrials.gov) - Jan 30, 2023
P2, N=21, Active, not recruiting, Sponsor: Maxivax SA
Not yet recruiting --> Withdrawn Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2023 --> Jan 2023
- ||| MVX-ONCO-1 / Release Therap
Enrollment change, Trial primary completion date, Metastases: SAKK 11/16: Personalized and Cell-based Antitumor Immunization MVX-ONCO-1 in Advanced HNSCC (clinicaltrials.gov) - Sep 1, 2022
P2, N=21, Recruiting, Sponsor: Maxivax SA
Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2023 --> Jan 2023 N=41 --> 21 | Trial primary completion date: Dec 2022 --> Jul 2023
- | MVX-ONCO-2 / MaxiVAX
Trial completion date, Trial initiation date, Trial primary completion date: MVX-ONCO-2 in Advanced Solid Tumors (clinicaltrials.gov) - Aug 24, 2022
P1, N=6, Not yet recruiting, Sponsor: Maxivax SA
N=41 --> 21 | Trial primary completion date: Dec 2022 --> Jul 2023 Trial completion date: May 2027 --> Dec 2027 | Initiation date: Mar 2022 --> Sep 2022 | Trial primary completion date: Dec 2022 --> Jul 2023
- || MVX-ONCO-1 / Release Therap
Enrollment closed, Trial completion date, Trial primary completion date: MVX-2011-01: MVX-ONCO-1 in Patients With Solid Tumor (clinicaltrials.gov) - Jan 27, 2022
P1, N=34, Active, not recruiting, Sponsor: Maxivax SA
Trial completion date: May 2027 --> Dec 2027 | Initiation date: Mar 2022 --> Sep 2022 | Trial primary completion date: Dec 2022 --> Jul 2023 Recruiting --> Active, not recruiting | Trial completion date: Dec 2021 --> Dec 2026 | Trial primary completion date: Dec 2021 --> Mar 2022
- | MVX-ONCO-2 / MaxiVAX
Trial initiation date: MVX-ONCO-2 in Advanced Solid Tumors (clinicaltrials.gov) - Jan 27, 2022
P1, N=6, Not yet recruiting, Sponsor: Maxivax SA
Recruiting --> Active, not recruiting | Trial completion date: Dec 2021 --> Dec 2026 | Trial primary completion date: Dec 2021 --> Mar 2022 Initiation date: Nov 2021 --> Mar 2022
- || MVX-ONCO-2 / MaxiVAX
New P1 trial: MVX-ONCO-2 in Advanced Solid Tumors (clinicaltrials.gov) - Oct 7, 2021
P1, N=6, Not yet recruiting, Sponsor: Maxivax SA
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Opdivo (nivolumab) / Ono Pharma, BMS
[VIRTUAL] MVX-ONCO-1 in advanced refractory cancers: Safety, feasibility, and preliminary efficacy results from all HNSCC patients treated in two ongoing clinical trials. () - Apr 29, 2021 - Abstract #ASCO2021ASCO_4621;
P1, P2
Preliminary efficacy data shows an encouraging rate of tumor control including prolonged CR in patients subsequently treated with nivolumab or chemotherapy . Efficacy of the concurrent use of anti-PD-1 and MVX-ONCO will be assessed in a planned clinical trial.
- | MVX-ONCO-1 / Release Therap
Enrollment closed, Metastases: SAKK 11/16: Personalized and Cell-based Antitumor Immunization MVX-ONCO-1 in Advanced HNSCC (clinicaltrials.gov) - Jan 13, 2021
P2, N=41, Active, not recruiting, Sponsor: Swiss Group for Clinical Cancer Research
Efficacy of the concurrent use of anti-PD-1 and MVX-ONCO will be assessed in a planned clinical trial. Recruiting --> Active, not recruiting
- | MVX-ONCO-1 / Release Therap
Trial completion date, Trial primary completion date: MVX-2011-01: MVX-ONCO-1 in Patients With Solid Tumor (clinicaltrials.gov) - Dec 17, 2020
P1, N=35, Recruiting, Sponsor: Maxivax SA
Recruiting --> Active, not recruiting Trial completion date: Dec 2019 --> Dec 2021 | Trial primary completion date: Dec 2019 --> Dec 2021
- | MVX-ONCO-1 / Release Therap
Trial completion date, Trial primary completion date, Metastases: SAKK 11/16: Personalized and Cell-based Antitumor Immunization MVX-ONCO-1 in Advanced HNSCC (clinicaltrials.gov) - Jun 18, 2020
P2, N=41, Recruiting, Sponsor: Swiss Group for Clinical Cancer Research
Trial completion date: Dec 2019 --> Dec 2021 | Trial primary completion date: Dec 2019 --> Dec 2021 Trial completion date: Dec 2024 --> Dec 2027 | Trial primary completion date: Jun 2020 --> Dec 2022
- | MVX-ONCO-1 / Release Therap
Enrollment open, Metastases: SAKK 11/16: Personalized and Cell-based Antitumor Immunization MVX-ONCO-1 in Advanced HNSCC (clinicaltrials.gov) - May 13, 2020
P2, N=41, Recruiting, Sponsor: Swiss Group for Clinical Cancer Research
Trial completion date: Dec 2024 --> Dec 2027 | Trial primary completion date: Jun 2020 --> Dec 2022 Active, not recruiting --> Recruiting
- | MVX-ONCO-1 / Release Therap
Enrollment closed, Enrollment change, Metastases: SAKK 11/16: Personalized and Cell-based Antitumor Immunization MVX-ONCO-1 in Advanced HNSCC (clinicaltrials.gov) - May 7, 2020
P2, N=7, Active, not recruiting, Sponsor: Swiss Group for Clinical Cancer Research
Active, not recruiting --> Recruiting Recruiting --> Active, not recruiting | N=41 --> 7
- | MVX-ONCO-1 / Release Therap
Enrollment change, Trial completion date, Trial primary completion date: MVX-2011-01: MVX-ONCO-1 in Patients With Solid Tumor (clinicaltrials.gov) - Sep 28, 2018
P1, N=35, Recruiting, Sponsor: Maxivax SA
Recruiting --> Active, not recruiting | N=41 --> 7 N=25 --> 35 | Trial completion date: Dec 2017 --> Dec 2019 | Trial primary completion date: Sep 2017 --> Dec 2019
- | MVX-ONCO-1 / Release Therap
Enrollment open, Metastases: SAKK 11/16: Personalized and Cell-based Antitumor Immunization MVX-ONCO-1 in Advanced HNSCC (clinicaltrials.gov) - Jun 27, 2017
P2, N=41, Recruiting, Sponsor: Swiss Group for Clinical Cancer Research
N=25 --> 35 | Trial completion date: Dec 2017 --> Dec 2019 | Trial primary completion date: Sep 2017 --> Dec 2019 Not yet recruiting --> Recruiting
- | MVX-ONCO-1 / Release Therap
Trial initiation date, Metastases: SAKK 11/16: Personalized and Cell-based Antitumor Immunization MVX-ONCO-1 in Advanced HNSCC (clinicaltrials.gov) - Mar 6, 2017
P2, N=41, Not yet recruiting, Sponsor: Swiss Group for Clinical Cancer Research
Not yet recruiting --> Recruiting Initiation date: Mar 2017 --> Jun 2017
- MVX-ONCO-1 / MaxiVAX
Enrollment change, Trial primary completion date: MVX-2011-01: MVX-ONCO-1 in Patients With Solid Tumor (clinicaltrials.gov) - Feb 9, 2017
P1, N=25, Recruiting, Sponsor: Maxivax SA
Initiation date: Mar 2017 --> Jun 2017 N=15 --> 25 | Trial primary completion date: Dec 2016 --> Sep 2017
- MVX-ONCO-1 / Release Therap
New P2 trial, Metastases: SAKK 11/16: Personalized and Cell-based Antitumor Immunization MVX-ONCO-1 in Advanced HNSCC (clinicaltrials.gov) - Dec 21, 2016
P2, N=41, Not yet recruiting, Sponsor: Swiss Group for Clinical Cancer Research
- MVX-ONCO-1 / MaxiVAX
Trial primary completion date: MVX-2011-01: MVX-ONCO-1 in Patients With Solid Tumor (clinicaltrials.gov) - Mar 24, 2016
P1, N=15, Recruiting, Sponsor: Maxivax SA
N=15 --> 25 | Trial primary completion date: Dec 2016 --> Sep 2017 Trial primary completion date: Nov 2015 --> Dec 2016
- MVX-ONCO-1 / MaxiVAX
Trial primary completion date: MVX-2011-01: MVX-ONCO-1 in Patients With Solid Tumor (clinicaltrials.gov) - Apr 14, 2015
P1, N=15, Recruiting, Sponsor: Maxivax SA
Trial primary completion date: Nov 2015 --> Dec 2016 Trial primary completion date: Apr 2015 --> Nov 2015
- MVX-ONCO-1 / MaxiVAX
New P1 trial: MVX-2011-01: MVX-ONCO-1 in Patients With Solid Tumor (clinicaltrials.gov) - Jul 17, 2014
P1, N=15, Recruiting, Sponsor: Maxivax SA